drugset

drugset / Trial / NCT00153153

Extended Use of Polyethyleneglycol3350 Laxative in Constipated Patients

NCT00153153 ↗

Phase 4 Completed 300 enrolled Braintree Laboratories

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the safety and efficacy of extended use of polyethyleneglycol3350 laxative as compared to placebo in constipated patients.

Timeline

Start: 2003-08
Primary completion: 2004-12
Completion: —

Publications

Menees SB, Lembo AJ, Chey WD. Polyethylene Glycol 3350 in the Treatment of Chronic Idiopathic Constipation: Post hoc Analysis Using FDA Endpoints. Can J Gastroenterol Hepatol. 2022 Sep 9;2022:3533504. doi: 10.1155/2022/3533504. eCollection 2022.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	polyethylene glycol	Other / unclassified	17 g	—

Indications